Evaluation of C-C Motif Chemokine Receptor 5 ( CCR5 ) as a Sample Adequacy Control in HPV Molecular Diagnostics

Reliable Human Papillomavirus (HPV) testing and genotyping are essential for quality assurance in HPV-based primary screening, disease management and for monitoring the impact of HPV vaccination. The clinical validation of HPV molecular diagnostic assays has significantly contributed to these object...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Diagnostics (Basel) 2024-09, Vol.14 (19), p.2194
Hauptverfasser: Njoku, Ruth C, Martinelli, Marianna, Giubbi, Chiara, De Marco, Sofia, Torsello, Barbara, d'Avenia, Morena, Sironi, Manuela, Bianchi, Cristina, Cocuzza, Clementina E
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Reliable Human Papillomavirus (HPV) testing and genotyping are essential for quality assurance in HPV-based primary screening, disease management and for monitoring the impact of HPV vaccination. The clinical validation of HPV molecular diagnostic assays has significantly contributed to these objectives; however, little emphasis has been placed on assuring sample quality. This study aimed to evaluate the accuracy of sample cellularity assessment using the ( ) gene target as a marker of sample adequacy in molecular diagnostics. Jurkat cell line samples were counted using both a Thoma cell-counting chamber and Fluorescence-Activated Cell Sorting (FACS). Jurkat cell line samples at three different concentrations were subsequently evaluated using the OncoPredict HPV Quality Control (QC) real-time PCR assay, employing for molecular cellularity quantification. The cellularity values obtained were comparable across the three different methods for all dilutions of the cell line tested. : The results obtained from this study show that represents a promising molecular marker for the accurate quantification of sample cellularity, confirming its use as a reliable sample adequacy control, thus reducing the risk of "false-negative" results.
ISSN:2075-4418
2075-4418
DOI:10.3390/diagnostics14192194